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Thymoma is the most common tumor of the anterior mediastinum. This tumor is associ-ated with unique paraneoplastic syndromes, 
such as myasthenia gravis, hypogammaglobulinemia, 
and pure red cell aplasia.1,2 The rarity of this tumor, 
however, has somewhat obscured the optimal treat-
ment for this disease. For the majority of patients who 
present with localized tumor, surgical extirpation re-
mains the standard of choice.2 However, radical resec-
tion is not always feasible for locally advanced stages 
III and IVA in the staging of Masaoka and associates3 
and these tumors should be approached in a multidis-
ciplinary fashion. 
Chemotherapy or radiotherapy or both can be 
used either as the first line of therapy to increase the 
ability to perform a radical resection or after surgery 
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BACKGROUND AND OBJECTIVES: complete surgical resection is the main goal in the treatment of thymoma, 
but is not always achievable in stage iii and iVa thymoma because of local invasion of the neighboring organs or 
the presence of diffuse pleural or pericardial implants. We reviewed our experience in multimodality treatment 
of advanced stage (iii and iVa) thymic tumors to evaluate the effectiveness and safety in patients with locally 
advanced unresectable thymoma. 
PATIENTS AND METHODS: We studied patients with newly diagnosed, histologically proven, unresectable 
malignant thymoma who underwent a multimodality treatment regimen that consisted of neoadjuvant che-
motherapy (three courses of cisplatin and etoposide), followed by surgical resection, postoperative radiation 
therapy, and consolidation chemotherapy (three courses of cisplatin and etposide). 
RESULTS: nine patients were consecutively enrolled from december 2001 to June 2007, and all were valuable 
for assessment. disease responded to neoadjuvant chemotherapy completely in 1 patient (11%) and partially in 
6 patients (66%) with an overall response of 77%. two patients had a minor response (22%). eight patients had 
surgical resection; 1 refused surgery. tumors were removed completely in 5 patients (62.5%) and incompletely 
in 3 (37.5%). all patients received radiation therapy and consolidation chemotherapy. seven patients were alive 
(77% at 4 years), with a median follow-up of 31 months, and 6 patients were disease free (66.6% disease-free 
survival at 4 years). the major side effect from neoadjuvant and consolidation chemotherapy was myelosup-
pression. 
CONCLUSION: the multimodality treatment of stage iii and iVa thymic tumors by integration of surgery, radio-
therapy, and chemotherapy, contributed to a good long-term outcome. the neoadjuvant chemotherapy improves 
the resectability rate and the survival of locally advanced stages of the disease. 
to reduce the incidence of recurrence. Adjuvant radio-
therapy seems to improve local control and survival.4-6 
In more advanced disease, systemic therapy has been 
demonstrated to produce a 50% to 80% objective 
response rate.7 The concept of combined-modality 
therapy is attractive for patients with thymoma in 
whom the burden of tumor volume is located in the 
mediastinum.8 During the last 10 to 15 years, several 
phase II trials have evaluated different therapeutic 
strategies in patients with locally advanced and ad-
vanced thymoma.9 These observations have led to the 
development of multimodality therapy for the treat-
ment of patients with advanced thymoma. The aim of 
the study was to evaluate the role of multimodality 
therapy in the treatment of locally advanced stage III 
and IVA malignant thymoma.
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PATIENTS AND METHODS
Nine patients with Masaoka stage III or IVA tumors 
were enrolled in this study. The resectability of disease 
was determined by the thoracic surgeons before the pa-
tients entered the protocol. Patients had a WHO per-
formance status of 2, bidimensional measurable disease, 
adequate bone marrow (absolute granulocyte counts 
≥1500 cells/mm3 and platelet counts ≥100 000 cells/
mm3), adequate hepatic function (serum total bilirubin 
level ≤1.5 mg/dL, and adequate renal function (serum 
creatinine level ≤1.5 mg/dL and creatinine clearance 
≥80 mL/min). Left ventricular ejection fraction in all 
participants was examined by two-dimensional echocar-
diography before treatment. Signed informed consent 
was obtained, a complete medical history and physical 
examination were taken, a laboratory work up including 
hematological profile, kidney and liver functions before 
and between chemotherapy, computed tomography were 
obtained at the beginning, before and after surgery and 
the end of treatment, at six months and then once a year 
during follow up. A CT scan was repeated after induc-
tion chemotherapy to evaluate the response: complete 
remission was described as the complete disappearance 
of the tumor mass; partial remission was defined as a de-
crease of 50% or more in the size of the lesion; and stable 
disease was defined as a regression of less than 50% of the 
mass with no new lesions appearing and no deterioration 
of patient performance. The profiles of patients before 
operation are shown in Table 1.
Treatment protocol
The treatment protocol consisted of three courses of 
neoadjuvant chemotherapy, surgical resection, radiation 
therapy and three courses of consolidation chemother-
apy. The neoadjuvant chemotherapy consisted of cispla-
tin, 75mg/m2 on days 1 and etoposide 100 mg/m2 on 
day 1 to day 3, repeated every 3- to 4-weeks for three 
courses. After 3 to 4 weeks from the last neoadjuvant 
chemotherapy course, computed tomography was per-
formed to assess the tumor resectability which was fol-
lowed by surgery. 
The operations were performed through a full me-
dian sternotomy in all patients. A complete excision of 
the tumor was always attempted. Whenever this proved 
impossible, the residual tumor was clipped to better 
define the radiation therapy portals. All patients un-
derwent an extended thymectomy. After median ster-
Table 1. Patient profiles before surgery.
Patient Sex Age (years) Who performance Masoaka    stage Histology
Paraneoplastic 
syndrome
1 Female 33 0 111 epithelial Myasthenia gravis
2 Male 51 1 111 epithelial -
3 Male 45 1 1va Lymphocytic -
4 Female 50 1 111 Mixed -
5 Male 65 2 111 Mixed Myasthenia gravis
6 Female 32 1 1va Lymphocytic -
7 Male 37 0 111 Mixed Systemic lupus erythematosus 
8 Male 46 1 1va Mixed Myasthenia gravis
9 Male 54 1 111 epithelial -
Table 2. Site of infiltration of surrounding structures in 8 patients. 
Number of 
infiltrations Percentage Structure
3 37.5% Lung
3 37.5% Pericardium
2 25% Superior vena cava
2 25%
Left 
brachiocephalic 
vein
1 12.5% Heart
2 25% ascending aorta
2 25% Main pulmonary artery
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notomy, both pleural envelopes were opened widely by 
elevating each hemi-sternum and incising the parietal 
pleura lateral to the mediastinal reflection to facilitate 
complete removal of all possibly involved mediastinal 
pleura. An accurate assessment of the gross extent of 
the tumor and its invasiveness, then inspection of the 
total pleural (parietal and visceral) surface for droplet 
metastases was performed. If the tumor was found to 
be small, apparently noninvasive, and readily movable, 
a total thymectomy was done (including the cervical 
tongues) with removal of all mediastinal fat around the 
tumor. If an invasive tumor was found, en bloc removal 
of affected pericardium, pleura, lung, and phrenic nerve 
was performed in addition to the total thymectomy. 
Radiotherapy to the mediastinal or residual tumor 
areas was performed using opposite anterior and pos-
terior parallel fields at doses of 45 Gy delivered for a 
period of 5 weeks over 25 fractions using a linear ac-
celerator 6MV photon machine. Then three cycles of 
the same chemotherapy were given. Survival was cal-
culated from the date of the diagnosis until the date of 
the last follow-up.
RESULTS
From December 2001 to June 2007, a total of 9 patients 
were consecutively enrolled in the study. Six patients 
were males. Three patients were diagnosed by CT-
guided biopsy and the rest of the patients by anterior 
mediastinotomy. The mean age was 45.9 years (range 
32-65 years), three patients had myathenia gravis. Six 
patients were Masoaka stage III. 
Neoadjuvant chemotherapy produced a complete 
response in 1 patient (11%), partial responses in 6 pa-
tients (66%), with an overall major response rate of 77% 
and 2 patients (22%) had a minor response. Eight pa-
tients had surgical resection; 1 refused surgery. Tumors 
were removed completely in 5 (62.5%) patients and in-
completely in 3 (37.5%). 
Those 3 patients (37.5%) had incomplete resection 
after induction chemotherapy and radiological evidence 
of invasion of the great vessels (ascending aorta, main 
pulmonary artery, superior vena cava and heart) was 
confirmed at anterior mediastinotomy before induction 
chemotherapy; extended full-thickness tumor invasion 
of the vessels was still present at operation and was the 
reason for incomplete resection. Only debulking was 
done for the latest 3 patients with no trial of vascular or 
pericardial reconstruction. 
At the time of surgical exploration, 3 patients were 
found to have already had tumor invasion into the peri-
cardium; 3 into the lung parenchyma; 2 into the great 
vessels, including the innominate veins, the superior 
vena cava, the aorta, or the pulmonary arteries; and 1 
into the heart. The site of infiltration of the surround-
ing structures in all patients is reported in Table 2.
All the patients had received radiation therapy and 
consolidation chemotherapy and only one patient re-
fused the last two cycles. Seven patients (77%) were alive 
at 4 years with a median follow-up of 31 months and 6 
patients(66%) had disease-free survival at 4 years. 
Toxicity
A total of 52 cycles of chemotherapy were taken. 
Myelosuppression was the most common hemato-
logical side effect with grade 3 neutropenia occurring 
in two patients. One developed febrile neutropenia. 
There was grade 3 anemia in two patients, and throm-
bocytopenia grade 3 in one patient. Fatigue, alopecia, 
and vomiting were the most common non-hemato-
logical toxicities (Table 3).
Table 3.  Toxicty of chemotherapy.
Toxicity
Grade 
1-2 
(n)
(%)
Grade 
3-4 
(n)
(%)
Neutropenia 3 33 2 22
Febrile neutropenia 1 11
Thrombocytopenia 2 22 1 11
anemia 4 44 2 22
alopecia 5 55 2 22
Fatigue 4 44 1 11
Nausea and vomiting 3 33 1 11
Neurology 1 11 0 0
Mucositis 1 11 1 11
Table 4. Post-operative complications.
   Complications Number
   Sternal dehiscence 1
   Pulmonary embolism 1
   Suppurative wound infection 1
   Mechanical ventilation >24h 1
   Pleural effusion 1
   Reoperation for bleeding 0 
   Pneumonia 1
   Myesthenic symptoms 1
   Mortality 0
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There was no operative mortality or sternal reopen-
ing for bleeding in our study. Postoperative surgical com-
plications were observed in 7 patients and included one 
case of sternal dehiscence, which was managed success-
fully by sternal rewiring, one with pulmonary embolism, 
which was managed with conservative medical treat-
ment, and one with recurrent bilateral pleural effusions 
that previously had systemic lupus erythrematosus and 
pleural effusions before the operation and that respond-
ed markedly to repeated thoracocentesis. One patient 
experienced acute respiratory distress syndrome after 
surgical resection and was mechanically ventilated and 
then weaned off successively after two days. The rest of 
the postoperative complications are shown in Table 4.
DISCUSSION
Surgical intervention is the most effective treatment 
modality for thymoma. Although surgery remains the 
mainstay in the treatment of thymoma, the best strat-
egy and which multimodality treatment should be ad-
opted in the more advanced and invasive tumors have 
yet to be determined. The main goal to achieve in the 
treatment of thymic cancers is the complete removal of 
the neoplasm, and on the basis of the experience with 
other neoplasms, it may be reached by integration of 
surgery, radiotherapy, and chemotherapy.10-12 
Radical resection, postoperative control of residual 
tumor, and prevention of local and distant recurrence 
should be pursued if cure rather than prolonged sur-
vival is to be achieved. En bloc resection of the primary 
tumor and the involved structures is certainly one of the 
keys to success.13,14 
Long-term survival has been reported despite the 
necessity of resecting and replacing the superior vena 
cava (SVC); hence, SVC involvement should not de-
termine complete resection. Pleural implants should 
be removed by extrapleural dissection, which can lead 
to long-term survival, although if multiple pleural im-
plants are found preoperatively, systemic therapy before 
surgery is preferred.15 In our study, there were two pa-
tients with gross invasion of the SVC for whom only 
debulking was performed as there was also involvement 
of the heart in one patient and the ascending aorta in 
the second patient, where clips were implanted to mark 
areas of close margins or residual disease to assist the 
radiation oncologist in treatment planning.
Macchiarini et al, were among the first to evaluate 
preoperative chemoradiotherapy in patients with po-
tentially resectable disease. They demonstrated that 
seven patients with clinical stage III thymoma received 
three cycles of cisplatin, epirubicin, and etoposide before 
surgery. Four patients experienced complete remission, 
whereas the remaining three patients developed either 
microscopic disease in two patients or gross residual 
disease in one patient.16 
In our study, due to the rarity of this neoplasm, 
only nine patients with advanced disease were enrolled. 
Cisplatin and etoposide chemotherapy were chosen due 
to the previous EORTC lung cancer cooperative group 
using this regimen in 16 patients with advanced and 
metastatic disease, and also in recurrent disease, which 
was a highly effective regimen with overall response of 
60%.17 In our study, the overall response was 77%, but 
this may be because our patients were newly diagnosed 
and there was no metastatic or recurrent disease.
A similar trial was also developed by Rea et al.18 
Sixteen patients with stage III and stage IVA disease 
were treated with a doxorubicin, cisplatin, vincristine, 
and cyclophosphamide regimen every 3 weeks for 
three to four cycles. After chemotherapy, surgery was 
performed, and if residual disease was present, post-
operative radiation therapy was given. Patients with a 
complete remission received three additional cycles of 
chemotherapy. Results of this trial demonstrated seven 
complete and five partial responses and a projected 2-
year survival rate of 80%, which was comparable to our 
study in which the overall survival is 77% in 4 years.
In another study by Kim et al, using the multimodal-
ity treatment, the intergroup trial studying PAC (cispla-
tin, adriamycin and cyclophosphamide) chemotherapy 
surgery and radiation in 23 patients demonstrated a 
high response rate of around 70%, which was also com-
parable to our study.19 
Cisplatin and etoposide is a common regimen in 
nonsmall and small cell bronchogenic tumors, which 
is safe and has predictable toxicity.20,21 In our study all 
the toxicities were predictable and comparable to other 
studies using this regimen. However, it has been also 
suggested by a previous report22 that even though the 
radicality of the operation is a prognostic factor when-
ever an invasive thymic tumor was resected after neoad-
juvant chemotherapy, it may be crucial that the goal of 
complete tumor clearance be achieved through a multi-
modality treatment. Moreover, radiotherapy may prove 
to be more effective after neoadjuvant chemotherapy 
and surgery, both because of the effect of radiosensibil-
ity induced by chemotherapy and because of a smaller 
disease mass, which can be treated better by radio-
therapy.22 The optimal coordination of chemotherapy, 
radiation therapy, and surgery has yet to be defined. 
Consequently, there is a need for prospective, rapid-ac-
cruing intergroup-driven trials to help identify the opti-
mal therapy of this disease.23
Death after thymoma resection in the periopera-
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tive period is now rare and should be less than 1%. 
Historically, the majority of deaths have occurred in 
patients with myathenia gravis from respiratory com-
plications with poorly controlled myasthenia.24 In the 
current study, there were no operative or in-hospital 
deaths due to the modern preoperative preparation and 
intensive care. In two cases, plasmapheresis had been es-
sentially performed.
In conclusion, multimodality treatment is an effec-
tive treatment of stage III and IVA thymic tumors; 
neoadjuvant chemotherapy improves the resectability 
rate and the survival of locally advanced stages of thy-
moma. However, a larger series of patients, and future 
prospective multi-institutional studies are needed to 
further verify or define the best treatment for this pa-
tient population.
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